Simplify Asset Management Inc. Sells 270,600 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Simplify Asset Management Inc. cut its position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 77.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 80,714 shares of the company's stock after selling 270,600 shares during the quarter. Simplify Asset Management Inc. owned 0.15% of Fulcrum Therapeutics worth $379,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its position in shares of Fulcrum Therapeutics by 223.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 569,185 shares of the company's stock worth $2,032,000 after purchasing an additional 393,202 shares in the last quarter. State Street Corp grew its holdings in shares of Fulcrum Therapeutics by 61.4% in the 3rd quarter. State Street Corp now owns 1,680,229 shares of the company's stock valued at $5,998,000 after acquiring an additional 638,955 shares in the last quarter. Barclays PLC increased its position in shares of Fulcrum Therapeutics by 367.1% in the third quarter. Barclays PLC now owns 124,141 shares of the company's stock valued at $443,000 after acquiring an additional 97,565 shares during the last quarter. Braidwell LP bought a new position in Fulcrum Therapeutics in the third quarter valued at approximately $3,817,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Fulcrum Therapeutics during the 3rd quarter worth approximately $474,000. Institutional investors and hedge funds own 89.83% of the company's stock.

Remove Ads

Fulcrum Therapeutics Trading Up 2.3 %

FULC stock traded up $0.07 during trading hours on Thursday, hitting $3.09. 139,022 shares of the stock were exchanged, compared to its average volume of 936,376. Fulcrum Therapeutics, Inc. has a 12 month low of $2.78 and a 12 month high of $10.13. The firm has a market capitalization of $166.80 million, a P/E ratio of -9.97 and a beta of 2.20. The company has a 50-day simple moving average of $3.55 and a two-hundred day simple moving average of $3.80.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.03). On average, equities research analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "neutral" rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $8.63.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.